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Introduction: Recent genome-wide association studies in Caucasians
revealed association with lung cancer risk of single nucleotide poly-
morphisms (SNPs) in the locus containing two nicotine acetylcholine
receptorCHRNA genes. However, the reported risk SNPs are extremely
rare in Asians. This study sought to identify other variants on CHRNA3
associated with lung cancer susceptibility and to explore whether SNPs
of CHRNA3 are of prognostic factors in patients with non-small cell
lung cancer (NSCLC) in Chinese Han population.
Methods: A case-control study of 529 cases and 567 controls was
performed to study the association of three SNPs (rs3743076,
rs3743078, and rs3743073) in CHRNA3 with lung cancer risk in
Chinese Han population using logistic regression models. The rela-
tionship between CHRNA3 polymorphisms with overall survival
among 122 patients with advanced stage (stage IIIb and IV) NSCLC
were evaluated using Cox multiple model based on the International
Association for the Study of Lung Cancer recommended tumor,
node, metastasis new staging.
Results: Patients with genotypes TG or GG for the novel SNP
rs3743073 in CHRNA3 gene, compared with those with TT, showed
an increased risk of lung cancer (adjusted odds ratio  1.91; 95%
confidence interval, 1.38–2.63; p  9.67  105) and worst
survival (adjusted hazard ratio  2.35; 95% confidence interval,
1.05–5.26; p  0.04) in patients with advanced stage NSCLC based
on International Association for the Study of Lung Cancer recom-
mended tumor, node, metastasis new staging.
Conclusions: These results suggest that the rs3743073 polymor-
phism in CHRNA3 is predictive for lung cancer risk and prognostic
in advanced stage NSCLC in Chinese Han population.
Key Words: Lung cancer, CHRNA3, Polymorphism, Case-control
study, Survival.
(J Thorac Oncol. 2010;5: 658–666)
Lung cancer is the most common cause of cancer mortalityworldwide.1 Although smoking is known to be one of the
most important risk factors, the fact that only a portion of
smokers develop lung cancer during their lifetime suggests
that other genetic and epigenetic factors are of importance in
determining individual’s susceptibility to lung cancer.2
Recently, the locus containing two genes encoding nico-
tine acetylcholine receptor (nAChR) subunits, CHRNA3 and
CHRNA5, was shown to be associated with lung cancer risk in
Caucasians by three genome-wide association (GWA) stud-
ies.3–5 CHRNA proteins are expressed in lung epithelial cells and
bind nicotine, an addictive compound in cigarette smoke, and
nitrosamines, potential lung carcinogens in cigarette smoke and
foods.6,7 Signal transduction through CHRNA proteins was sug-
gested to cause cell proliferation and also to facilitate neoplastic
transformation.8,9 A decreased survival correlation with lung
cancer has been shown10,11 because the reduced treatment effi-
cacy and the worse survival may be well explained by the
nAChRs pathway through CHRNA proteins on tumor cell pro-
liferation, apoptosis, epithelial-mesenchymal transition, and pro-
invasive and angiogenic effects.8,9
These exciting results in the GWA studies encouraged
us to investigate the association between the risk single
nucleotide polymorphisms (SNPs) (rs8034191, rs1051730,
and rs16969968) reported in Caucasians3–5 with lung cancer
risk in Chinese populations. However, by examining the
HapMap data, these three risk SNPs are extremely rare in
Asians, suggesting that the role these SNPs play in risk of
lung cancer in Asian populations, if any, may not be as
important as they do in Caucasians. Thus, we hypothesized
that if CHRNA polymorphisms also play a role in suscepti-
bility to lung cancer in Chinese populations, there must be
other risk variants. Therefore, we conducted a case-control
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study about three novel SNPs, rs3743076, rs3743078, and
rs3743073, located in CHRNA3 based on the HapMap data
and the reported studies,12,13 to examine the association of
CHRNA3 polymorphisms with risks for three major histo-
logic types of lung cancer, adenocarcinoma (ADC), squa-
mous cell carcinoma (SQC), and small cell lung cancer
(SCLC), in a Chinese Han population. We hypothesize fur-
ther that CHRNA3 polymorphisms may be associated with
survival outcomes in lung cancer.
PATIENTS AND METHODS
Case-Control Study
All cases and controls were Chinese Han Population.
The cases consisted of 356 ADC, 131 SQC, and 42 SCLC
patients of Shanghai Chest Hospital affiliated with Shaghai
Jiaotong University from 2005 to 2008. The controls consist-
ing of 567 healthy residents were selected by random sam-
pling from 11 independent communities in Shanghai Pudong
New Area and Baoshan district during the same time period
as the cases were recruited. All the lung cancer cases without
a history of other cancer, from whom informed consents and
blood samples were obtained, were consecutively included in
this study. All the lung cancer cases were diagnosed as ADC,
SQC, or SCLC by histologic examinations according to
World Health Organization classification confirmed by two
independent pathologists. Routine tumor, node, metastasis
(TNM) staging was performed according to the new staging
project initiated by the International Association for the Study
of Lung Cancer in 2009.14,15 All the control subjects were
selected with a criterion of no history of any cancer. A
standard informed consent of the control subjects was ap-
proved and obtained by the ethics committee of the Shanghai
Institute for Biologic Sciences.
Smoking history of cases and controls was obtained
through interview using a questionnaire. Smoking dose of
each subject was expressed by “cigarettes per day,” i.e., the
number of cigarettes smoked per day on average on most
days; smoking exposure of each subject was expressed by
“pack-years,” which was defined as the number of pack per
day (i.e., cigarettes per day divided by 20) multiplied by years
of smoking as in previous studies.3–5 Smokers were defined
as those who had smoked regularly for 12 months or longer
at any time in their life, whereas nonsmokers were defined as
those who had not. There were no individuals who had
smoked regularly for less than 12 months.
Genotyping
Blood samples were collected from all study partic-
ipants. DNA was extracted from peripheral blood samples
using the Tiangen Biotech kit (DP318; Tiangen Biotech
(Beijing) Co., Ltd., Beijing China) The three novel geno-
type SNPs, rs3743076, rs3743078, and rs3743073 in
CHRNA3 locus, were selected based on the fact that minor
allele frequencies (MAFs) in the Chinese Han population
are reported to be 10% in the dbSNP database (http://
www.ncbi.nlm.nih.gov/SNP/) and the reported studies.12,13
The CHRNA3 polymorphisms were genotyped by the 5-
nuclease assay (TaqMan) using the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA). Genotyping was performed by laboratory person-
nel blinded to sample status, and a random 5% of the samples
were repeated to validate genotyping procedures. Two au-
thors independently reviewed the genotyping results, data
entry, and statistical analyses.
Outcome Collection
Survival analysis was carried out in patients with
non-small cell lung cancer (NSCLC) (ADC and SQC)
because of the limited statistical power of the relatively
smaller numbers of patients with SCLC (n  42). Data
were collected from at least one of the following sources:
the inpatient and outpatient records of Shanghai Chest
Hospital, the follow-up registries of Shanghai Municipal
Center for Disease Control and Prevention, and patient or
family contact. Patients distribution is listed in Figure 1.
Of all 487 patients with NSCLC, 44 (44 of the 487, 9.0%)
patients were excluded from survival analyses because of
no adequate blood for genotyping and 25 (25 of the 487,
5.1%) were excluded because of no survival data. There
were no significant differences in clinical information
between those who had blood available for genotyping and
those who did not, and no differences between those who
had survival data and those who did not.
Overall survival (OS) was calculated from date of a
definite diagnosis to date of death or the last known date
alive. The last follow-up date was November 6, 2009. A total
of 296 patients with early-stage (stage I, II, and IIIa) NSCLC
continued to be visited because of relatively short median
follow-up time of 18.5 months. One hundred twenty-two
patients with advanced stage (stage IIIb and IV) NSCLC were
available for survival analysis with a median follow-up of
21.5 months (range, 12.3–57.0 months). The patients who
received chemotherapy were defined as those who received
first-line platinum-based chemotherapy for at least two cy-
cles, whereas patients who did not receive chemotherapy
were defined as those who had not received first-line plati-
num-based chemotherapy. Response Evaluation Criteria in
Solid Tumors (RECIST) was introduced to standardize tumor
response assessment. One hundred three of 122 (84.4%)
patients with advanced-stage NSCLC receiving chemother-
apy were assessable for efficacy evaluation. Efficacy results
for the platinum-based chemotherapy were summarized as
follows: progressive disease or its converse, disease control
rate, consisting of complete response, partial response, and
stable disease.
Statistical Methods
A Hardy-Weinberg equilibrium test was performed
using the SHEsis software (http://www.nhgg.org/analysis).16
Calculation of the D and r2 values as well as haplotype
estimation was undertaken using the expectation-maximi-
zation algorithm of the same software.16 The information
was compared across genotype and clinical records using
Pearson 2 tests (for categoric variables) and Kruskal-
Wallis tests (for continuous variables), where appropriate.
The strength of association of alleles with ADC, SQC, and
SCLC risks was measured as crude odds ratios (ORs). To
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minimize the confounding effects from gender and smok-
ing status, we performed the stratified analysis for each
SNP on gender and smoking status individually. The
strength of association of genotypes was further measured
as ORs adjusted for additional parameters, including gen-
der, age, and smoking status, using an unconditional mul-
tivariate logistic regression analysis, a second way to
control for confounding effects. The associations between
CHRNA3 polymorphism status and survival were esti-
mated using the method of Kaplan-Meier and assessed
using the log-rank test. Cox regression models were used
to adjust for potential confounders, with CHRNA3 geno-
types fitted as indicator variables. These statistical analy-
ses were performed using SPSS 15.0 statistical software
(SPSS Inc., Chicago, IL). A level of p  0.05 for an odds
ratio was considered significant.
RESULTS
Identification of a Lung Cancer Susceptibility
Locus on 15q25
We conducted a case-control study consisting of 529
cases and 567 controls (Table 1). All the subjects were
Chinese Han population. Most of the SQC and SCLC cases
were male and smokers, whereas nearly 50% of ADC cases
were smokers, as has been reported.17 All the cases and
controls were genotyped for the three SNPs (Table 2). All
these SNPs were in Hardy-Weinberg equilibrium both in
cases and controls (p  0.05). One SNP, rs3743073 located
in CHRNA3 gene, showed significant allelic differentiations
irrespective of histologic types, smoking status, and gender,
whereas the other two SNPs, rs3743076 and rs3743078, did
not show significant allelic differentiations (Table 2). Thus, it
was indicated that SNP rs3743073 was associated with lung
cancer risk in this population. To control the confounding
effects further, adjusted ORs by age, gender, and smoking
status for genotypes of rs3743073 were calculated (Table 3).
Patients with genotypes TG or GG for the novel SNP
rs3743073 in CHRNA3 gene, compared with those with TT,
showed an increased risk of lung cancer (adjusted odds
ratio  1.91; 95% confidence interval, 1.38–2.63; p 
9.67 105, Table 3). Meanwhile, ORs of heterozygotes and
homozygotes for the reference genotype were consistently
increased among populations irrespective of histologic types,
smoking status, and gender (Table 3).
FIGURE 1. Patients distribution.
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We next examined linkage disequilibrium (LD) among
these three SNPs located in one gene CHRNA3, and haplo-
types were estimated. The LD structure (rs3743076/
rs3743078/rs3743073) is shown in Figure 2. LD coefficients
(D and r2) among the three variants (Figure 3) suggested
that the degree of LD was relatively high. So, haplotypes
were constructed with all three variants, and the frequen-
cies of haplotypes were then analyzed by excluding the
rare haplotypes (those 3% frequency in cases or con-
trols). The result revealed a significant difference in the
distribution of the global haplotypes between cases and
controls (p  8.74  1012, Table 4). We also observed
TABLE 1. Lung Cancer Cases and Controls Used for a Case-Control Study
Variable Control
Cases
All ADC SQC SCLC
Total 567 529 356 131 42
Age (mean  SD, yr) 59  9 58  10 57  10 61  9 60  10
Gender (%) 192 (33.9) 355 (67.1) 191 (53.7) 124 (94.7) 40 (95.2)
Male
Female 375 (66.1) 174 (32.9) 165 (46.3) 7 (5.3) 2 (4.8)
Smoking status (%) 480 (84.7) 238 (45.0) 218 (61.2) 14 (10.7) 6 (14.3)
Nonsmokers
Smokers 87 (15.3) 291 (55.0) 138 (38.8) 117 (89.3) 36 (85.7)
Pack-years (mean  SD)a 27.9  18.7 38.8  22.5 32.8  20.5 45.0  20.5 41.9  29.6
Cigarettes per day, CPD (mean  SD)a 16.3  8.7 23.9  11.6 22.4  11.8 25.5  10.2 24.0  14.3
Duration of smoking (mean  SD, yr)a 34.3  10.6 31.9  10.4 28.7  10.3 35.2  8.8 33.6  11.5
a Value for smokers.
ADC, adenocarcinoma; SQC, squamous cell carcinoma; SCLC, small cell lung cancer.
TABLE 2. Allele Differentiation between Controls and Cases
SNP Allele Category
Frequency (%)
OR (95% CI) pControl Case
rs3743076 T All 840 (74.6) 736 (72.7) 1.10 (0.91–1.34) 0.33
ADC 487 (71.6) 1.16 (0.94–1.44) 0.16
SQC 183 (72.6) 1.11 (0.81–1.51) 0.52
SCLC 66 (82.5) 0.62 (0.35–1.13) 0.11
Nonsmokers 705 (74.1) 326 (72.1) 1.10 (0.86–1.42) 0.44
Smokers 135 (77.6) 410 (73.2) 1.27 (0.85–1.89) 0.25
Male 283 (74.1) 496 (72.7) 1.07 (0.81–1.42) 0.63
Female 557 (74.9) 240 (72.7) 1.12 (0.83–1.50) 0.46
rs3743078 G All 271 (24.2) 240 (24.0) 1.01 (0.83–1.24) 0.90
ADC 159 (23.6) 1.03 (0.83–1.29) 0.77
SQC 60 (24.0) 1.01 (0.73–1.39) 0.95
SCLC 21 (26.9) 0.87 (0.52–1.46) 0.59
Nonsmokers 230 (24.3) 109 (24.3) 1.00 (0.78–1.30) 0.98
Smokers 41 (23.8) 131 (23.6) 1.01 (0.68–1.51) 0.96
Male 94 (24.7) 153 (22.8) 1.12 (0.83–1.50) 0.47
Female 177 (23.9) 87 (26.4) 0.88 (0.65–1.18) 0.39
rs3743073 G All 520 (45.9) 523 (54.3) 1.40 (1.18–1.66) 1.49  104
ADC 346 (53.7) 1.37 (1.13–1.66) 1.60  103
SQC 131 (54.1) 1.39 (1.05–1.84) 0.02
SCLC 46 (59.0) 1.69 (1.06–2.70) 0.03
Nonsmokers 449 (46.9) 230 (54.2) 1.34 (1.07–1.69) 0.01
Smokers 71 (40.8) 293 (54.3) 1.72 (1.22–2.43) 2.03  103
Male 182 (47.4) 350 (53.7) 1.29 (1.00–1.66) 0.05
Female 338 (45.2) 173 (55.4) 1.51 (1.16–1.97) 2.32  103
Genotype data were missing for 27 subjects (27 of 1096, 2.46%) for rs3743076, 35 subjects (35 of 1096, 3.19%) for rs3743078, and 48
subjects (48 of 1096, 4.38%) for rs3743073.
CI, confidence interval; ADC, adenocarcinoma; SQC, squamous cell carcinoma; SCLC, small cell lung cancer.
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that the TCT haplotype frequency was significantly lower
in cases than in controls, whereas the TCG haplotype was
significantly higher in cases than in controls (both p 
0.0001, Table 4). Subjects carrying the TCG haplotype had
a 6.57-fold (p  5.19  1012, Table 4) increased lung
cancer risk compared with the other haplotypes.
We further examined the association of the polymor-
phisms of rs3743073 with smoking status in lung cancer
smokers. The values of cigarettes per day and pack-years
were used as measures of smoking doses of subjects for this
analysis because the values were commonly used in previous
three GWA studies.3–5 Values of cigarettes per day and
pack-years of individuals with the risk allele of rs3743073
were higher than those without the risk allele in all cases and
NSCLC group (ADC and SQC) and slightly lower in SCLC
group; however, the difference did not reach a statistical
significance (p  0.05, Table 5).
Association of rs3743073 SNP with Advanced
Stage NSCLC Prognosis
Patients characteristics are listed in Table 6. Given that
the direction of effect was the same in the TG and GG
genotypes of lung cancer susceptibility analysis, we com-
bined the TG and GG genotypes for survival analysis. There
were no significant differences by CHRNA3 genotype status
in patient-, tumor-, or treatment-related factors such as age,
gender, smoking status, stage, histology, and chemotherapy
status (p  0.05, Table 6).
Univariate survival analysis demonstrated that OS was
prolonged among the patients with the TT genotype com-
pared with the TG/GG genotypes (log-rank p 0.037, Figure
4). Cox multiple OS analysis showed that patients carrying
the TG/GG genotype had a poorer survival than patients with
the TT genotype (adjusted hazard ratio for death, 2.35; 95%
TABLE 3. Genotype Differentiation for rs3743073 between Controls and Cases
SNP Category Genotype
No. of
Controls (%)
No. of
Cases (%)
Adjusted OR
(95% CI) Adjusted p Value
rs3743073 Alla TT 166 (29.3) 100 (20.7) Reference
TG 280 (49.5) 241 (50.0) 1.79 (1.27–2.52) 0.001
GG 120 (21.2) 141 (29.3) 2.16 (1.46–3.19) 1.20  104
TG  GG 400 (70.7) 382 (79.3) 1.91 (1.38–2.63) 9.67  105
ADCa TT 70 (21.7) Reference
TG 158 (49.1) 1.61 (1.12–2.31) 0.010
GG 94 (29.2) 2.07 (1.38–3.13) 0.001
TG  GG 252 (78.3) 1.75 (1.25–2.46) 0.001
SQCa TT 24 (19.8) Reference
TG 63 (52.1) 2.32 (1.23–4.39) 0.010
GG 34 (28.1) 2.31 (1.12–4.79) 0.024
TG  GG 97 (80.2) 2.32 (1.27–4.22) 0.006
SCLCa TT 6 (15.4) Reference
TG 20 (51.3) 2.99 (1.08–8.32) 0.036
GG 13 (33.3) 3.63 (1.20–11.00) 0.023
TG  GG 33 (84.6) 3.21 (1.22–8.48) 0.018
Nonsmokersb TT 133 (27.8) 38 (17.9) Reference
TG 243 (50.7) 118 (55.7) 1.72 (1.12–2.64) 0.013
GG 103 (21.5) 56 (26.4) 1.93 (1.18–3.14) 0.009
TG  GG 346 (72.2) 174 (82.1) 1.78 (1.19–2.68) 0.005
Smokersb TT 33 (37.9) 62 (23.0) Reference
TG 37 (42.5) 123 (45.6) 1.91 (1.07–3.39) 0.028
GG 17 (19.5) 85 (31.5) 2.63 (1.33–5.17) 0.005
TG  GG 54 (62.1) 208 (77.0) 2.15 (1.26–3.65) 0.005
Malec TT 58 (30.2) 73 (22.4) Reference
TG 86 (44.8) 156 (47.9) 1.91 (1.18–3.11) 0.009
GG 48 (25.0) 97 (29.8) 1.88 (1.10–3.24) 0.022
TG  GG 134 (69.8) 253 (77.6) 1.90 (1.21–2.99) 0.005
Femalec TT 108 (28.9) 27 (17.3) Reference
TG 194 (51.9) 85 (54.5) 1.76 (1.07–2.88) 0.025
GG 72 (19.3) 44 (28.2) 2.46 (1.40–4.33) 0.002
TG  GG 266 (71.1) 129 (82.7) 1.95 (1.21–3.12) 0.006
a Adjusted for age, gender, and smoking status.
b Adjusted for age and gender.
c Adjusted for age and smoking status.
OR, odds ratio; CI, confidence interval; ADC, adenocarcinoma; SQC, squamous cell carcinoma; SCLC, small cell lung cancer.
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confidence interval, 1.05–5.26; p  0.04, Table 7), with
adjustment for important prognostic factors (age, gender,
smoking status, stage, histology, and chemotherapy) between
the two groups.
DISCUSSION
In this study, we examined whether the most significant
SNPs on CHRNA3 are also associated with risk of lung
cancer in Chinese Han populations. For the fact that allele
frequencies in Asians of reported risk SNPs, rs8034191,
rs1051730, and rs16969968, were lower than that in Cauca-
sians,18 this study sought to identify other variants on
CHRNA3 associated with lung cancer susceptibility in Chi-
nese. On the basis of analysis of 529 lung cancer cases and
567 controls derived from Chinese Han populations, we
found that rs3743073GT in the CHRNA3 gene located on
chromosome 15q25 were significantly associated with in-
creased risk of lung cancer irrespective of histologic types,
smoking status, and gender. In addition, we showed that
carrying G allele of rs3743073 was associated with signifi-
cantly worst survival among patients with advanced stage
NSCLC. Together, our results support CHRNA3 located on
chromosome 15q25 as a susceptibility region for lung cancer
FIGURE 3. Linkage disequilibrium (LD) structure of the
single nucleotide polymorphism (SNP) in CHRNA3 (D/r2
value). Pairwise D values are color coded: high D values
are dark, low D values are light (values were generated
by SHEsis software16). The numbers shown at the top rep-
resent the degrees of the location of the region on chro-
mosome 15 (Chr 15).
FIGURE 2. Linkage disequilibrium (LD) structure at 15q25 in individuals in CHB (Han Chinese in Beijing, China). Boxes are
shaded according to D derived in Haploview (v4.0).
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and indicated that risk allele G of rs3743073 may be as a
worst prognostic indicator for patients with advanced stage
NSCLC.
We consider these findings important because our data
underscore the difference in genetic markers among different
ethnic populations. Recently, a Japanese study reported that
the three risk SNPs of rs8034191, rs1051730, and
rs16969968, described in previous GWA studies in Cauca-
sians,3–5 were also associated with lung cancer risk in a
Japanese population.19 However, a recent Chinese study
showed that these three risk SNPs were not significantly
associated with lung cancer risk in Chinese populations.12
Allele frequencies in Asians of rs8034191, rs1051730, and
rs16969968 were lower than that in Caucasians.18 For
rs8034191, the MAFs were reported to be 0.42, 0.16, and
0.03 in whites, African Americans, and Chinese, respectively.
Likewise, for rs1051730, the MAFs were 0.39, 0.15, and
0.04; for rs16969968, the MAFs were 0.39, 0.08, and 0.04,
respectively, based on the HapMap data. The Japanese find-
ings19 inconsistent with that reported Chinese study12 might
also reflect the difference among different populations.
Effects of CHRNA SNPs according to histologic types
of lung cancers were examined in a previous study4 and were
similar among ADC, SQC, and SCLC. In this study, the risk
allele of rs3743073 also showed similarly and significantly
increased ORs among different pathologic subtype (Tables 2
and 3), indicating that rs3743073 SNPs are associated with
lung cancer risk irrespective of histologic types of cancer. In
NSCLC and SCLC, the same nAchR3-5-7-4 subunits
as mentioned for the human bronchial epithelium cells are
expressed,20,21 and NSCLC and SCLC cell lines can both
TABLE 4. Estimated Haplotype Frequencies and Association Significance
Haplotypea n (%)
2 OR (95% CI) prs3743076 rs3743078 rs3743073 Case Control
A C G 249 (26.1) 272 (24.4) 1.07 1.11 (0.91–1.36) 0.30
T C G 66 (6.9) 13 (1.1) 47.69 6.57 (3.57–12.08) 5.19  1012
T C T 390 (41.0) 561 (50.3) 15.96 0.70 (0.59–0.83) 6.53  105
T G G 202 (21.1) 216 (19.4) 1.28 1.13 (0.91–1.40) 0.26
T G T 30 (3.1) 47 (4.2) 1.57 0.74 (0.46–1.19) 0.21
Global 57.72 8.74  1012
a Those with frequency 0.03 in both control and case have been excluded.
OR, odds ratio; CI, confidence interval.
TABLE 5. Analyses between Genotypic Differentiation of
rs3743073 with Cigarettes per Day and Pack-Years of Lung
Cancer Smokers
Genotype p Value by
Kruskal-
Wallis TestTT TG GG
No. of cigarettes/d
(mean  SD)
All patients (n  291) 22  12 25  11 24  12 0.19
ADC (n  138) 22  13 23  11 23  11 0.67
SQC (n  117) 22  10 27  11 26  9 0.08
SCLC (n  36) 28  13 22  10 24  19 0.50
Pack-years (mean  SD)
All patients (n  291) 34  22 42  22 39  23 0.08
ADC (n  138) 30  19 36  21 34  21 0.41
SQC (n  117) 38  23 48  20 47  20 0.12
SCLC (n  36) 50  29 40  26 37  33 0.51
ADC, adenocarcinoma; SQC, squamous cell carcinoma; SCLC, small cell lung
cancer.
TABLE 6. CHRNA3 Genotype Distribution in 122 Advanced
Stage NSCLC Patients
Characteristic
rs3743073
p
TT
(n  20)
TG  GG
(n  102)
Age, yr 0.40a
Median  SD 54  10 56  11
Range 34–67 22–78
Gender 1.00b
Male 12 (60.0%) 62 (60.8%)
Female 8 (40.0%) 40 (39.2%)
Smoking status 0.81b
Smokers 10 (50.0%) 48 (47.1%)
Nonsmokers 10 (50.0%) 54 (52.9%)
IASLC recommended TNM new stagingc 1.00b
Stage IIIb 4 (20.0%) 21 (20.6%)
Stage IV 16 (80.0%) 81 (79.4%)
Histology 0.73b
ADC 18 (90.0%) 86 (84.3%)
SQC 2 (10.0%) 16 (15.7%)
Platinum-based chemotherapyd 0.11b
DCR (RPs  SDs) 17 (85.0%) 60 (58.8%)
PD 2 (10.0%) 24 (23.5%)
Nonchemo 1 (5.0%) 18 (17.6%)
a P values were calculated by Wilcoxon test.
b P values were calculated by Pearson 2 test.
c TNM denotes tumor-node-metastasis based on the International Association for
the Study of Lung Cancer (IASLC) recommended TNM new staging.14,15 Percentages
may not total 100 because of rounding.
d The patients who received chemotherapy were defined as those who received
first-line platinum-based chemotherapy for at least two cycles, whereas patients who did
not receive chemotherapy were defined as those who had not received first-line
platium-based chemotherapy. One hundred three of 122 (84.4%) patients with ad-
vanced-stage NSCLC receiving chemotherapy were assessable for efficacy evaluation.
DCR, disease control rate; PR, partial response; SD, stable disease; PD, progressive
disease.
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synthesize and release Ach.22 Increased levels of Ach provide
endogenous proliferative stimuli to nAchR, suggesting that
an autocrine or a paracrine cholinergic pathway loop for
nAchR in NSCLC and SCLC. The lung cancer cell prolifer-
ation, apoptosis, epithelial-mesenchymal transition, and pro-
invasive and angiogenic effects are therefore reinforced by an
autocrine or a paracrine loop.8,9,23
Studies investigating the CHRNA polymorphisms in
relation to survival outcomes have been few. An Italian study
reported that there is no significant association of the
CHRNA5 D398N polymorphism with the clinical stage of
lung ADC cancer.24 TNM staging is a prognostic factor for
lung cancer; however, it does not account for survival differ-
ences within the same stage. Moreover, as the 13th World
Conference on Lung Cancer was held in San Francisco from
July 31, 2009, to August 4, 2009, a new TNM staging (7th
edition) was published by the International Association for
the Study of Lung Cancer because the previous TNM stage
cannot predict OS accurately. Based on this TNM new
staging project, we found worse survival among patients with
advanced stage NSCLC carrying the variant G allele of
rs3743073. The CHRNA3 gene encodes different subunits of
nicotinic acetylcholine receptors, which are members of a
superfamily of ligand-gated ion channels that mediate rapid
signal transmission at synapses. On one hand, nicotine after
initiation may contribute to the progression phase and sur-
vival outcomes of cancer development23; on the other hand, it
can cause resistance to gemcitabine, cisplatin, and paclitaxel
in NSCLC by activation of Akt by DhE-sensitive 3
nAChRs.25 The interaction of nicotine with CHRNA3 plays a
key role in the worse survival and the reduced treatment
efficacy by the nAChRs pathway. The expression of these
receptors can be inhibited by nicotine receptor antagonists of
3 subunits, which implies possible chemoprevention oppor-
tunities for lung cancer.26 Of interest will be whether nAChRs
pathway polymorphisms can be used to predict benefit from
nicotine receptor antagonists.
Association of CHRNA SNPs with lung cancer risk by
dividing subjects into smokers and nonsmokers was exam-
ined in two GWA studies,4,5 with values of cigarettes per day
and pack-years investigated in three GWA studies.3–5 In the
Iceland, Spain, and The Netherland study, the individuals
with one and two copies of the minor allele for the rs1051730
SNP were estimated to smoke approximately one and two
more cigarette per day than those without.3 Association with
risk in smokers was commonly observed in other two GWA
studies,4,5 whereas association in nonsmoker was not.5 In this
study, the risk allele of rs3743073 showed similarly increased
ORs in both smokers and nonsmokers (Tables 2 and 3),
indicating that CHRNA3 SNPs are associated with lung can-
cer risk irrespective of smoking, which was consistent with
the study by Hung et al.4 and the recent Japanese study.19 In
addition, no association of rs3743073 SNPs with cigarettes
per day and pack-years in lung cancer cases was demon-
strated in our data, consistent with the recent report about
rs3743073 in European population.13 Reasons underlying the
racial difference in the genotype with smoking associations
are unclear.5 This discrepancy may be due to differences in
TABLE 7. Cox Multiple Analysis for Overall Survival in 122
Patients with Advanced Stage NSCLC
Characteristic
OS
Adjusted HR 95% CI p
Agea 1.00 0.98–1.03 0.89
Gender
Male Reference
Female 0.84 0.42–1.67 0.62
Smoking status
Smokers Reference
Nonsmokers 0.57 0.30–1.12 0.10
IASLC recommended TNM new staging
Stage IIIb Reference
Stage IV 1.93 1.04–3.58 0.04
Histology
ADC Reference
SQC 1.87 0.96–3.63 0.06
Platinum-based chemotherapy
DCR Reference
PD 0.83 0.47–1.46 0.51
Nonchemo 1.98 1.05–3.73 0.03
rs3743073
TT Reference
TG  GG 2.35 1.05–5.26 0.04
a Age calculated as continuous variables.
OS, overall survival; HR, hazard ratio; ADC, adenocarcinoma; CI, confidence
interval; SQC, squamous cell carcinoma; DCR, disease control rate; PD, progressive
disease; IASLC, International Association for the Study of Lung Cancer; TNM, tumor,
node, metastasis.
FIGURE 4. Kaplan-Meier survival curves about rs3743073
genotype in 122 patients with advanced stage non-small cell
lung cancer (NSCLC). The curves of patients with CHRNA3
genotype TT (n  20), TG  GG (n  102) were shown as
blue and green lines, respectively. Follow-up was shown
truncated at 21 months. Log-rank analysis indicated signifi-
cant differences between OS curves (p  0.037). OS, overall
survival; MST, median survival time; NR, not reach.
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genetic and environmental backgrounds. Alternatively, other
factors that have not been taken into account, such as food
intake and passive smoking,6,7 differentiate the mode of
contribution of the CHRNA SNPs in nonsmokers. Because
the results of these studies are inconsistent, further studies are
still needed to draw a conclusion on this issue.
There are still several limitations to our study. First,
because of the relative smaller number of SCLC cases in our
group, a larger sample with sufficient histologic subtypes of lung
cancer is needed to investigate for better understanding this issue
among different histologic subtypes. In addition, a longer fol-
low-up period is needed to investigate the CHRNA polymor-
phisms with lung cancer survival in all staging, especially in
early stage. Second, the factors of gender and smoking status
in the case and control groups were imbalanced. Considering
this aspect, two methods were used in our analysis to control
the imbalanced factors. (1) The stratified analysis on gender
and smoking status were performed to ensure a balanced
distribution of confounding factor, individually. (2) Uncon-
ditional multivariate logistic regression model, including gen-
der, age, and smoking status, provided another way to control
for confounders. Third, there is still debate regarding the true
function of the polymorphisms. The candidate SNP in our
study resides in the intron 3 of CHRNA3 gene, 64 base pairs
away from exon 4. It might function by altered binding of
transcription factors and altered splicing of gene, or even
through LD with truly functional sites, but so far unknown.
Further functional experiments on this SNP are needed to
explore the mechanism by which rs3743073 in CHRNA3
affects lung cancer.
In conclusion, we identified a novel rs3743073 SNP in
CHRNA3 gene on chromosome 15q25 with lung cancer risk
in Chinese Han populations, and the allele G of rs3743073
associated with an increased lung cancer risk was also asso-
ciated with poor survival in patients with advanced stage
NSCLC. Further studies are warranted to confirm these find-
ings in different ethnic populations. We are planning to
investigate the addition of nicotine receptor antagonists to the
treatment of patients with lung cancer.
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